GlassScriptPhysician profile
Christina Messinger
NPI 1336717305
$11,350.87
in general payments reported to CMS, 2019-2025
26 companies · $2,532 in 2025
The $2,532 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $986 · 2023: $2,751 · 2024: $4,470 · 2025: $2,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,123 · Consulting Fee: $1,063 · Education: $514 · Travel and Lodging: $55.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,122.72 |
| Consulting Fee | $1,062.50 |
| Education | $513.74 |
| Travel and Lodging | $55.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,335.02 | 2022-2025 | Tremfya |
| Abbvie INC. | $2,008.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $835.14 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $688.41 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $612.24 | 2021-2025 | Ilumya |
| Genzyme Corporation | $577.16 | 2022-2025 | |
| Ucb, INC. | $512.22 | 2021-2025 | Bimzelx |
| Incyte Corporation | $444.52 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $419.09 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $401.64 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $319.24 | 2022-2025 | |
| Galderma Laboratories, L.P. | $227.74 | 2023-2025 | Aklief, Nemluvio, Epsolay |
| Botanix Sb INC | $193.62 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $123.83 | 2021 | |
| Pfizer INC. | $119.33 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $111.13 | 2021-2025 | Cabtreo, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.62 | 2022-2024 | Spevigo |
| Leo Pharma INC. | $87.28 | 2022-2025 | Anzupgo, Adbry |
| Dermavant Sciences, INC. | $68.96 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $41.16 | 2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $24.98 | 2024 | Zoryve |
| Mayne Pharma Commercial LLC | $22.54 | 2022 | |
| Sandoz INC. | $18.40 | 2024 | |
| Biofrontera INC. | $17.77 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $15.50 | 2025 | Vtama |
| Almirall LLC | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Messinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.